SCHEMBL1020537

SCHEMBL1020537

S=C=Nc1cccc(Br)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MIF P14174 1/20 0.54
▸ EGFR P00533 1/20 0.47
▸ ALDH1A1 P00352 5/20 0.41
▸ CYP3A4 P08684 4/20 0.41
▸ P2RY6 Q15077 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ ALOX15 P16050 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ TDP1 Q9NUW8 3/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ PRCP P42785 1/20 0.41
▸ PTGES O14684 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ PNMT P11086 1/20 0.36
▸ IDO1 P14902 2/20 0.36
▸ TDO2 P48775 2/20 0.36
▸ HPGD P15428 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483888 0.84 MIF (0.67) MIFEGFRALDH1A1CYP3A4P2RY6
Bitoscanate SCHEMBL11598436 0.79 MIF (0.68) MIFEGFRALDH1A1CYP3A4P2RY6
SCHEMBL7172274 0.79 ALDH1A1 (0.46) ALDH1A1MEN1KMT2ATDP1PTGES
SCHEMBL7172271 0.79 ALDH1A1 (0.46) ALDH1A1MEN1KMT2ATDP1PTGES
SCHEMBL30102043 0.79 ALDH1A1 (0.46) ALDH1A1MEN1KMT2ATDP1PTGES
SCHEMBL59005 0.78 MAPK1 (0.45) ALDH1A1CYP3A4MEN1KMT2ATDP1
SCHEMBL9425791 0.77 MIF (0.44) MIFEGFRALDH1A1CYP3A4P2RY6
SCHEMBL20337 0.74 MIF (0.54) MIFALDH1A1CYP3A4P2RY6MEN1
SCHEMBL1804955 0.74 MIF (0.54) MIFEGFRALDH1A1CYP3A4P2RY6
SCHEMBL9701237 0.74 MIF (0.54) MIFALDH1A1CYP3A4P2RY6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12402638-B2 Materials and methods for extending shelf-life of foods JP LABORATORIES, INC. (US) 2025-09-02 — — US claimed
US-20250194617-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-06-19 — — US claimed
US-20250169514-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-05-29 — — US claimed
US-20250084759-A1 FLUORESCENT DYE OIL TRACER COMPOSITIONS SAUDI ARABIAN OIL COMPANY (SA) 2025-03-13 — — US claimed
US-12232516-B2 Materials and methods for extending shelf-life of foods JP LABORATORIES, INC. (US) 2025-02-25 — — US claimed
US-12193465-B2 Materials and methods for extending shelf-life of foods JP LABORATORIES, INC. (US) 2025-01-14 — — US claimed
CN-117924210-A Preparation method of 2-iminothiazolidine-4-ketone compound 赣南师范大学 2024-04-26 — — CN claimed
CN-114751868-B Diaryl substituted triazole acetic acid compound, and preparation method and application thereof 山东理工大学 2024-04-12 — — CN claimed
US-20230380457-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-30 — — US claimed
EP-4280882-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2023-11-29 — — EP claimed
US-20160250175-A1 COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE JC (WUXI) COMPANY, INC. (CN) 2016-09-01 — — US claimed
EP-3034076-A1 COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE JC (Wuxi) COMPANY, Inc. (CN) 2016-06-22 — — EP claimed
CN-103992265-B Two three bromo 1,3-bis-pyridine alkali propane and preparation method thereof, using method, recovery method and application XI'AN JIAOTONG UNIVERSITY (CN) 2016-02-24 — — CN claimed
CN-105267967-A Combined application of isothiocyanate-type compound and anti-cancer drug acting or affecting DNA WUXI JC PHARMACAUTICAL TECHNOLOGY INC 2016-01-27 — — CN claimed
CN-104415332-A Combined application between isothiocyanate-type compound and kinase inhibitor medicine in treatment of cancer WUXI JC PHARMACAUTICAL TECHNOLOGY INC 2015-03-18 — — CN claimed
CN-104117064-A Combined application of isothiocyanate compound and hormone medicine WUXI JC PHARMACAUTICAL TECHNOLOGY INC 2014-10-29 — — CN claimed
CN-103992265-A Double tribromo 1,3-bipyridine onium salt dimethylmethane, and preparation method, application method, recovery method and application thereof UNIV XI AN JIAOTONG 2014-08-20 — — CN claimed
WO-2010065329-A2 NANOPARTICLES FOR CANCER TREATMENT THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-06-10 — — WO claimed
US-20060241178-A1 Compositions and methods for treating lung cancer IMMUNEGUARD LLC (US) 2006-10-26 — — US claimed
WO-2004060365-A1 COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER AMERICAN HEALTH FOUNDATION (US) 2004-07-22 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160250175-A1 COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE CHUK, KIT, MKI67 MIF 986/4885EGFR 77/4885ALDH1A1 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback